why choose us

First received: September 20, 2022

Clinical Trial: A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Polycythemia Vera

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)

Brief Summary: This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV).At Week 36 of dosing, participants will be assessed for eligibility to receive additional treatment through Week 52.Participants deriving clinical benefit and safely tolerating bomedemstat will qualify for continued treatment at the Investigator's discretion.

Read more